- Home
- IMRX vs HLVX Comparison
IMRX vs HLVX Comparison
Compare IMRX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRX
- HLVX
- Stock Information
- Founded
- IMRX 2008
- HLVX 2020
- Country
- IMRX United States
- HLVX United States
- Employees
- IMRX N/A
- HLVX N/A
- Industry
- IMRX Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- IMRX Health Care
- HLVX Health Care
- Exchange
- IMRX Nasdaq
- HLVX Nasdaq
- Market Cap
- IMRX 73.2M
- HLVX 87.6M
- IPO Year
- IMRX 2021
- HLVX 2022
- Fundamental
- Price
- IMRX $1.72
- HLVX $1.90
- Analyst Decision
- IMRX Buy
- HLVX Hold
- Analyst Count
- IMRX 7
- HLVX 5
- Target Price
- IMRX $12.80
- HLVX $2.33
- AVG Volume (30 Days)
- IMRX 801.9K
- HLVX 245.3K
- Earning Date
- IMRX 11-13-2024
- HLVX 11-07-2024
- Dividend Yield
- IMRX N/A
- HLVX N/A
- EPS Growth
- IMRX N/A
- HLVX N/A
- EPS
- IMRX N/A
- HLVX N/A
- Revenue
- IMRX N/A
- HLVX N/A
- Revenue This Year
- IMRX N/A
- HLVX N/A
- Revenue Next Year
- IMRX N/A
- HLVX N/A
- P/E Ratio
- IMRX N/A
- HLVX N/A
- Revenue Growth
- IMRX N/A
- HLVX N/A
- 52 Week Low
- IMRX $1.00
- HLVX $1.55
- 52 Week High
- IMRX $8.07
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- IMRX 37.40
- HLVX 47.67
- Support Level
- IMRX $1.52
- HLVX $1.88
- Resistance Level
- IMRX $1.93
- HLVX $2.13
- Average True Range (ATR)
- IMRX 0.19
- HLVX 0.07
- MACD
- IMRX -0.05
- HLVX -0.01
- Stochastic Oscillator
- IMRX 21.95
- HLVX 15.56
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.